^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PBF-1129

    i
    Other names: PBF-1129, PBF 1129, PBF1129
    Associations

    News

    Trials
    Company:
    Palobiofarma, Xoma
    Drug class:
    Adenosine A2B receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Dwight Owen | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11)
    |
    Opdivo (nivolumab) • PBF-1129
    10ms
    PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=30, Suspended, Dwight Owen | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11)
    |
    Opdivo (nivolumab) • PBF-1129
    10ms
    PBF-1129 in Patients With NSCLC (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Palobiofarma SL | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Oct 2023 --> May 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK mutation • ROS1 mutation
    |
    PBF-1129
    over1year
    Improving combination therapies: Targeting A2B adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. (PubMed, J Natl Cancer Inst)
    Data identify A2BAR as a valuable therapeutic target to modify metabolic and immune TME to reduce immunosuppression, enhance the efficacy of immunotherapies, and support clinical application of PBF-1129 in combination therapies.
    Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma)
    |
    PBF-1129
    almost2years
    PBF-1129 in Patients With NSCLC (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Palobiofarma SL | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Oct 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK mutation • ROS1 mutation
    |
    PBF-1129
    2years
    PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Dwight Owen | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • PBF-1129
    2years
    PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Dwight Owen | Initiation date: Apr 2022 --> Nov 2022
    Trial initiation date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • PBF-1129
    almost3years
    PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Dwight Owen
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • PBF-1129
    over4years
    PBF-1129 in Patients With NSCLC (clinicaltrials.gov)
    P1, N=18, Recruiting, Palobiofarma SL | Trial completion date: Dec 2019 --> Jun 2023 | Trial primary completion date: Nov 2019 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK mutation • ROS1 mutation
    |
    PBF-1129